vs

Side-by-side financial comparison of Datavault AI Inc. (DVLT) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.

MESA LABORATORIES INC is the larger business by last-quarter revenue ($65.1M vs $33.8M, roughly 1.9× Datavault AI Inc.). MESA LABORATORIES INC runs the higher net margin — 5.6% vs 2.0%, a 3.6% gap on every dollar of revenue. On growth, Datavault AI Inc. posted the faster year-over-year revenue change (3649.6% vs 3.6%). MESA LABORATORIES INC produced more free cash flow last quarter ($18.0M vs $-734.0K). Over the past eight quarters, Datavault AI Inc.'s revenue compounded faster (1051.7% CAGR vs 5.1%).

Datavault AI Inc develops AI-powered data management and integration solutions, serving enterprise clients across the United States and North America. Its offerings help organizations unify disparate data assets, streamline analytics workflows, and accelerate machine learning model development and deployment.

Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.

DVLT vs MLAB — Head-to-Head

Bigger by revenue
MLAB
MLAB
1.9× larger
MLAB
$65.1M
$33.8M
DVLT
Growing faster (revenue YoY)
DVLT
DVLT
+3645.9% gap
DVLT
3649.6%
3.6%
MLAB
Higher net margin
MLAB
MLAB
3.6% more per $
MLAB
5.6%
2.0%
DVLT
More free cash flow
MLAB
MLAB
$18.8M more FCF
MLAB
$18.0M
$-734.0K
DVLT
Faster 2-yr revenue CAGR
DVLT
DVLT
Annualised
DVLT
1051.7%
5.1%
MLAB

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
DVLT
DVLT
MLAB
MLAB
Revenue
$33.8M
$65.1M
Net Profit
$661.0K
$3.6M
Gross Margin
89.3%
64.2%
Operating Margin
12.3%
12.2%
Net Margin
2.0%
5.6%
Revenue YoY
3649.6%
3.6%
Net Profit YoY
110.4%
316.6%
EPS (diluted)
$0.53
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DVLT
DVLT
MLAB
MLAB
Q4 25
$33.8M
$65.1M
Q3 25
$2.9M
$60.7M
Q2 25
$1.7M
$59.5M
Q1 25
$629.0K
$62.1M
Q4 24
$902.0K
$62.8M
Q3 24
$1.2M
$57.8M
Q2 24
$345.0K
$58.2M
Q1 24
$255.0K
$58.9M
Net Profit
DVLT
DVLT
MLAB
MLAB
Q4 25
$661.0K
$3.6M
Q3 25
$-33.0M
$2.5M
Q2 25
$-37.1M
$4.7M
Q1 25
$-9.6M
$-7.1M
Q4 24
$-1.7M
Q3 24
$-5.1M
$3.4M
Q2 24
$-42.7M
$3.4M
Q1 24
$2.7M
$-254.6M
Gross Margin
DVLT
DVLT
MLAB
MLAB
Q4 25
89.3%
64.2%
Q3 25
3.3%
61.5%
Q2 25
2.0%
62.0%
Q1 25
11.0%
61.8%
Q4 24
24.6%
63.3%
Q3 24
19.3%
61.3%
Q2 24
3.2%
64.0%
Q1 24
62.1%
Operating Margin
DVLT
DVLT
MLAB
MLAB
Q4 25
12.3%
12.2%
Q3 25
-508.1%
7.8%
Q2 25
-718.1%
5.1%
Q1 25
-1499.4%
2.4%
Q4 24
9.2%
Q3 24
-447.4%
6.1%
Q2 24
-1566.7%
9.6%
Q1 24
-1630.6%
-460.6%
Net Margin
DVLT
DVLT
MLAB
MLAB
Q4 25
2.0%
5.6%
Q3 25
-1135.5%
4.1%
Q2 25
-2139.3%
8.0%
Q1 25
-1520.3%
-11.4%
Q4 24
-2.7%
Q3 24
-434.5%
5.9%
Q2 24
-12366.7%
5.8%
Q1 24
1061.6%
-432.2%
EPS (diluted)
DVLT
DVLT
MLAB
MLAB
Q4 25
$0.53
$0.65
Q3 25
$-0.33
$0.45
Q2 25
$-0.54
$0.85
Q1 25
$-0.18
$-1.30
Q4 24
$-0.31
Q3 24
$-1.39
$0.63
Q2 24
$-11.89
$0.62
Q1 24
$-5.35
$-47.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DVLT
DVLT
MLAB
MLAB
Cash + ST InvestmentsLiquidity on hand
$2.0M
$29.0M
Total DebtLower is stronger
$68.4M
Stockholders' EquityBook value
$238.0M
$186.7M
Total Assets
$274.7M
$434.8M
Debt / EquityLower = less leverage
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DVLT
DVLT
MLAB
MLAB
Q4 25
$2.0M
$29.0M
Q3 25
$1.7M
$20.4M
Q2 25
$662.0K
$21.3M
Q1 25
$171.0K
$27.3M
Q4 24
$3.3M
$27.3M
Q3 24
$3.9M
$24.3M
Q2 24
$6.1M
$28.5M
Q1 24
$2.8M
$28.2M
Total Debt
DVLT
DVLT
MLAB
MLAB
Q4 25
$68.4M
Q3 25
$69.4M
Q2 25
$70.3M
Q1 25
$71.3M
Q4 24
$72.2M
Q3 24
$73.1M
Q2 24
$74.1M
Q1 24
Stockholders' Equity
DVLT
DVLT
MLAB
MLAB
Q4 25
$238.0M
$186.7M
Q3 25
$99.5M
$178.5M
Q2 25
$74.1M
$172.5M
Q1 25
$81.7M
$159.8M
Q4 24
$85.7M
$155.2M
Q3 24
$4.3M
$161.5M
Q2 24
$6.4M
$150.7M
Q1 24
$-2.7M
$145.4M
Total Assets
DVLT
DVLT
MLAB
MLAB
Q4 25
$274.7M
$434.8M
Q3 25
$138.7M
$430.4M
Q2 25
$120.7M
$435.7M
Q1 25
$95.7M
$433.3M
Q4 24
$100.6M
$433.3M
Q3 24
$8.0M
$454.1M
Q2 24
$10.6M
$440.4M
Q1 24
$6.9M
$446.8M
Debt / Equity
DVLT
DVLT
MLAB
MLAB
Q4 25
0.37×
Q3 25
0.39×
Q2 25
0.41×
Q1 25
0.45×
Q4 24
0.47×
Q3 24
0.45×
Q2 24
0.49×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DVLT
DVLT
MLAB
MLAB
Operating Cash FlowLast quarter
$-406.0K
$18.8M
Free Cash FlowOCF − Capex
$-734.0K
$18.0M
FCF MarginFCF / Revenue
-2.2%
27.7%
Capex IntensityCapex / Revenue
1.0%
1.1%
Cash ConversionOCF / Net Profit
-0.61×
5.17×
TTM Free Cash FlowTrailing 4 quarters
$37.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DVLT
DVLT
MLAB
MLAB
Q4 25
$-406.0K
$18.8M
Q3 25
$-10.4M
$8.2M
Q2 25
$-6.8M
$1.9M
Q1 25
$-6.0M
$12.7M
Q4 24
$-17.5M
$18.1M
Q3 24
$-4.2M
$5.3M
Q2 24
$-5.5M
$10.7M
Q1 24
$-3.5M
$12.9M
Free Cash Flow
DVLT
DVLT
MLAB
MLAB
Q4 25
$-734.0K
$18.0M
Q3 25
$7.1M
Q2 25
$884.0K
Q1 25
$-6.1M
$11.9M
Q4 24
$-17.6M
$17.3M
Q3 24
$-4.2M
$3.5M
Q2 24
$-5.5M
$9.9M
Q1 24
$-3.5M
$12.3M
FCF Margin
DVLT
DVLT
MLAB
MLAB
Q4 25
-2.2%
27.7%
Q3 25
11.7%
Q2 25
1.5%
Q1 25
-966.0%
19.2%
Q4 24
-1946.9%
27.6%
Q3 24
-361.7%
6.0%
Q2 24
-1599.7%
16.9%
Q1 24
-1390.6%
21.0%
Capex Intensity
DVLT
DVLT
MLAB
MLAB
Q4 25
1.0%
1.1%
Q3 25
0.0%
1.8%
Q2 25
0.0%
1.7%
Q1 25
8.3%
1.2%
Q4 24
3.9%
1.3%
Q3 24
0.7%
3.1%
Q2 24
4.1%
1.5%
Q1 24
2.4%
0.9%
Cash Conversion
DVLT
DVLT
MLAB
MLAB
Q4 25
-0.61×
5.17×
Q3 25
3.32×
Q2 25
0.40×
Q1 25
Q4 24
Q3 24
1.54×
Q2 24
3.17×
Q1 24
-1.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DVLT
DVLT

Eos Technology Holdings Inc.$30.0M89%
Consumer Audio Products Components And Other Revenue Net$3.2M9%

MLAB
MLAB

Sterilization And Disinfection Control$24.9M38%
Biopharmaceutical Development$14.4M22%
Other$14.1M22%
Clinical Genomics$11.8M18%

Related Comparisons